Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Next Previous
Trial Profile

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Anal cancer; Colorectal cancer; Gastrointestinal cancer; Pancreatic ductal carcinoma; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOBLET

Most Recent Events

  • 08 Sep 2025 Primary endpoint has been met. (efficacy based on objective response rate (ORR) and/or disease control rate assessed at week 16)
  • 10 Jul 2025 According to an Oncolytics media release, the company will host a key opinion leader (KOL) webinar on Tuesday, July 22, 2025, at 1:00 p.m. ET to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers.
  • 14 May 2025 According to an Oncolytics Biotech media release, company anticipates initial efficacy results from Cohort 5 of the GOBLET study investigating pelareorep combined with modified FOLFIRINOX with or without atezolizumab in newly diagnosed metastatic pancreatic cancer in H1 2026:

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top